Monoclonal antibody · Antagonist of alpha4beta7 integrin · developed by Takeda Pharms Usa
Vedolizumab is a humanized monoclonal antibody that binds the α4β7 integrin and blocks its interaction with MAdCAM-1, inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue. It is studied in ulcerative colitis and Crohn's disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 29, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06581328 | Phase 4 | Ulcerative Colitis | Recruiting | TAK |
| NCT06045754 | Phase 4 | Crohn's Disease | Recruiting | TAK |
| NCT04259138 | Phase 4 | Colitis, Ulcerative | Completed | TAK |
| NCT06732804 | Phase 1 | Healthy Male and Female Subjects | Completed | ALVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Crohn's DiseaseUlcerative ColitisColitis, UlcerativeHealthy Male and Female Subjects
Updated Oct 11, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →